Successful track record of developing and commercializing innovative and clinically significant healthcare technologies.
President and Chief Executive Officer
Scott brings over 20 years of executive experience in the medical device industry, having both founded and helmed numerous public and private companies in the medical device, biologics and healthcare IT space.
Scott served as a president and consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He has raised ~ $150m in equity in public and private entities. Scott currently serves on the Advamed Board of Directors and the Advamed Accel Board of Directors.
Prior to joining GI Dynamics, Scott served as a turnaround executive working on behalf of multiple venture capital and private equity firms. Scott served as president of Americas of Systagenix, the private equity buyout of the J&J Advanced Wound Care Division- sold to Acelity. Scott led the uplisting of PlasmaTech Biologics from the OTC to Nasdaq. He founded and led Innovative Spinal Technologies prior to its sale to Integra, and CentriMed, which was sold to the Global Healthcare Exchange (GHX). GHX transacted over $45bn in 2018 and has saved member organizations over $5bn since inception.
Scott began his medical device career as a sales representative for a surgical distributor, working for Anspach and Carl Zeiss. Scott served as a Scout Platoon Leader and Rifle Platoon Leader in the 82nd Airborne Division.
Scott holds a Bachelor of Arts and Bachelor of Engineering from Dartmouth College.
Chief Financal Officer
Charles brings over 15 years of experience as a finance executive in the medical industry, having worked with a wide variety of life sciences, therapeutics, and medical device companies.
Charles has been serving as a consulting finance executive to a broad array of life sciences companies for Danforth Advisors, LLC since February 2018, and previously from 2012 to 2015. In 2015, Charles joined the Guild for Human Services, Inc., as CFO then returned to Danforth Advisors to resume consulting for life science companies in February 2018.
During his time with Danforth, Charles has served as a senior finance executive for Marina Biotech (NASDAQ: MRNA) and Interleukin Genetics (NASDAQ: ILGN) and continues to serve as the head of finance for numerous privately and venture backed life science companies.
Prior to joining Danforth in 2012, Charles held the position of CFO for Aeris Therapeutics, Inc. and Intelligent Medical Devices, Inc., vice president of finance for Adnexus Therapeutics, Inc., and senior director of financial planning and analysis for Transkaryotic Therapies, Inc. (NASDAQ: TKT).
Charles holds an MBA and MS degree in Molecular Genetics and Cell Biology from the University of Chicago and a BS in Biology from Colgate University.
Vice President of Clinical and Regulatory Affairs
Stephen brings over 30 years of experience in development, regulatory, preclinical and clinical operations, quality and resource management with a focus on medical devices.
Prior to joining GI Dynamics, Stephen held the position of vice president of regulatory, clinical affairs and quality assurance at Neograft Technologies Inc. He also held leadership roles at Insulet Corporation, Boston Scientific Corporation Inc., and Phase Forward Inc., as well as vice president roles at PLC Medical Systems.
Stephen brings extensive knowledge of the diabetes disease and medical device space, where he has led 10 clinical trials, multiple CE Mark approvals, and numerous 510(k) clearances. Stephen holds nearly 20 United States and international patents and co-author of two peer-reviewed publications.
Stephen holds a BS in Physics from Bridgewater State College.